HanchorBio Secures $25M Series B to Propel Next-Generation Personalized Biotherapeutics Revolution

HanchorBio (漢康生技) is thrilled to announce a successful funding round of US$25,000,000, a pivotal milestone that will supercharge our mission to innovate in the field of personalized biotherapeutics. This infusion of capital reinforces our commitment to reactivating the immune system to combat diseases, with a specific focus on cancer and other debilitating conditions that continue to challenge modern medicine. With operations spanning San Francisco, Taipei, and Shanghai, our company is uniquely positioned at the intersection of innovation and global expertise. Led by a team of seasoned pharmaceutical industry veterans renowned for their track record in biologics discovery and worldwide development, HanchorBio is leveraging this investment to advance our proprietary Fc-based designer biologics (FBDB™) platform. The FBDB™ platform has already demonstrated promising proof-of-concept in several in-vivo animal models, and this new funding will accelerate efforts to refine its multi-targeting modalities that bridge both innate and adaptive immunity. We are channeling these funds into further research and development, bolstering our R&D infrastructure to explore groundbreaking molecular configurations and revolutionize manufacturing methodologies through enhanced CMC processes. Beyond the laboratory, these resources will empower the expansion of our clinical development pipeline, aiming to fill the current gaps in treatment for patients with unmet medical needs. At HanchorBio, our bold vision to rewrite immunotherapies is driving us to transform the future of medicine, offering renewed hope and innovative solutions where they are needed most.